Evidence map›Paper›PMID 30958379›Full record

ArticleJournal of Alzheimer's disease : JAD2019

Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers.

Tessandra Stewart, Min Shi, Aanchal Mehrotra, Patrick Aro, David Soltys, Kathleen F Kerr, Cyrus P Zabetian, Elaine R Peskind, Peggy Taylor, Leslie M Shaw and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Evaluation of ATNNeurology · 2024
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tessandra StewartDepartment of Pathology, University of Washington School of Medicine, Seattle, WA, USA.
Min ShiDepartment of Pathology, University of Washington School of Medicine, Seattle, WA, USA.
Aanchal MehrotraDepartment of Pathology, University of Washington School of Medicine, Seattle, WA, USA.
Patrick AroDepartment of Pathology, University of Washington School of Medicine, Seattle, WA, USA.
David SoltysDepartment of Pathology, University of Washington School of Medicine, Seattle, WA, USA.
Kathleen F KerrDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Cyrus P ZabetianParkinson's Disease Research and Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
Elaine R PeskindVeterans Affairs Northwest Network, Mental Illness Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
Peggy TaylorBioLegend, Dedham, MA, USA.
Leslie M ShawDepartment of Pathology and Laboratory Medicine and Center for Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, Philadelphia, PA, USA.
John Q TrojanowskiCenter for Neurodegenerative Disease Research (CNDR), University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Jing ZhangDepartment of Pathology, University of Washington School of Medicine, Seattle, WA, USA.
Alzheimer’s Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
Udall Center Director's meeting poster awardP50NS062684 · NINDS · UNIVERSITY OF WASHINGTON · PI MONTINE, THOMAS J · 2009 to 2020
$18.3M
Large Scale Biomarker Discovery and Validation for Parkinsons DiseaseU01NS082137 · NINDS · UNIVERSITY OF WASHINGTON · PI ZHANG, JING · 2012 to 2016
$6.0M
Peptide Biomarkers for Alzheimer DiseaseR01AG056711 · NIA · UNIVERSITY OF WASHINGTON · PI SHI, MIN · 2017 to 2021
$4.1M
Peptide Biomarkers for Parkinson DiseaseU01NS091272 · NINDS · UNIVERSITY OF WASHINGTON · PI SHI, MIN · 2016 to 2020
$2.1M
Exosomal transport of brain-derived proteins to the blood in Alzheimer diseaseR56AG057417 · NIA · UNIVERSITY OF WASHINGTON · PI ZHANG, JING · 2017 to 2017
$754k
Exploring microvesicular transport across the blood-brain barrier as a novel a-synuclein clearance mechanism and source of Parkinson's disease biomarkersR21NS104511 · NINDS · UNIVERSITY OF WASHINGTON · PI SHI, MIN · 2018 to 2019
$428k
Characterization and quantification of CNS cell specific extracellular microvesicles in bloodR21MH118160 · NIMH · UNIVERSITY OF WASHINGTON · PI STEWART, TESSANDRA · 2018 to 2019
$424k
NIA NIH HHS P30 AG010124NIA NIH HHS R01 AG056711NIA NIH HHS R56 AG057417NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904NIMH NIH HHS R21 MH118160NINDS NIH HHS P50 NS062684NINDS NIH HHS R21 NS104511NINDS NIH HHS U01 NS082137NINDS NIH HHS U01 NS091272
6 · The paper itself

Abstract

backgroundNeurodegenerative diseases require characterization based on underlying biology using biochemical biomarkers. Mixed pathology complicates discovery of biomarkers and characterization of cohorts, but inclusion of greater numbers of patients with different, related diseases with frequently co-occurring pathology could allow better accuracy. Combining cohorts collected from different studies would be a more efficient use of resources than recruiting subjects from each population of interest for each study.

objectiveTo explore the possibility of combining existing datasets by controlling pre-analytic variables in the Alzheimer's Disease Neuroimaging Initiative (ADNI) and Parkinson's Progression Markers Initiative (PPMI) studies.

methodsCerebrospinal fluid (CSF) was collected and processed from 30 subjects according to both the ADNI and PPMI protocols. Relationships between reported levels of Alzheimer's disease (AD) and Parkinson's disease (PD) biomarkers in the same subject under each protocol were examined.

resultsProtocol-related differences were observed for Aβ, but not t-tau or α-syn, and trended different for p-tau and pS129. Values of α-syn differed by platform. Conversion of α-syn values between ADNI and PPMI platforms did not completely eliminate differences in distribution. DISCUSSION: Factors not captured in the pre-analytical sample handling influence reported biomarker values. Assay standardization and better harmonized characterization of cohorts should be included in future studies of CSF biomarkers.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersDisease ProgressionFemaleHumansMaleMiddle AgedParkinson DiseasePeptide FragmentsPhosphorylationtau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAlzheimer’s diseaseamyloid-βParkinson’s diseasetauα-Synuclein

Identifiers

PMID30958379
PMCPMC6513710

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.